Abstract: Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

Abstract: The invention relates to mucoadhesive dispersion nanoparticle system applicable in pharmacy, medicine and cosmetics, especially by administration to surfaces with intensive physiological clearance such as nasal, pulmonal, ocular, oral, throat, rectal, vaginal etc. surfaces, as well as to the method for production such mucoadhesive dispersion nanoparticle system. The composition of mucoadhesive dispersion nanoparticle system comprising in an aqueous medium 0.01 to 2.00 w % hydroxypropyl methyl cellulose and from 0.10 to 10 w % dispersed solid lipid nanoparticles (SLN) for intracellular release of active substances. The advantages of the composition of SLN mucoadhesive dispersion nanoparticle system of the invention are an increased efficacy and controllable depo-effect for transport and delivery of active substances, forming of a continuous film over the applied epithelial surface and substantially increasing of the retention time of the applied dose.

Abstract: Compositions are provided which include at last one Dead Sea extract and at least one polysaccharide, wherein the repeating unit of said polysaccharide is a tetrasaccharide consisting of two D-glucose residues, one L-fucose residue and one D-glucuronic acid residue. Formulations include the compositions which are used as skin protectants against pollution.

Abstract: The disclosure relates to a method of making a bioceramic coating on a fibrous article for use in a medical implant, comprising steps of providing an article comprising fibers made from a biocompatible, non-biodegradable polymer; coating at least the fibers that will be in contact with bone upon use as an implant with a solution of a coating polymer to result in coated fibers having a coating polymer layer; treating the coated fibers with a dispersion of bioactive ceramic particles 0.01-10 ?m in a treating solvent comprising a solvent for the coating polymer in at least one step; and substantially removing the treating solvent; to result in the particles being partly embedded in the coating polymer layer of the coated fibers.

Abstract: The present invention includes compositions and methods preventing or reversing the symptoms of aging in a subject in need thereof comprising administering to the subject an amount of a composition comprising pterostilbene, nicotinamide, and optionally vitamin A (retinol), and one or more retinoids effective to prevent or reverse the symptoms of aging.

Abstract: The present disclosure relates to ready-to-use liquid aqueous bortezomib compositions bortezomib and pharmaceutical excipients. Other aspects include methods of preparing such ready-to-use liquid aqueous bortezomib compositions, and methods of using such ready-to-use liquid bortezomib compositions in therapeutic applications.

Abstract: Polyacrylamide-based copolymers act as stabilizing excipients in formulations of antibody biopharmaceutical agents without interacting directly with the antibody or altering its pharmacokinetic properties. The polyacrylamide-based copolymers confer a substantial stability benefit to high concentration compositions of a variety of antibodies by precluding adsorption of the antibody to the interfaces of the composition, preventing undesirable aggregation events and maintaining the binding activity of the antibody. Such antibody compositions are useful in methods of administering the composition to a subject.

Abstract: The invention provides to a powdered composition of additives and a method of use thereof for increasing the visibility, potency and coverage of disinfectant solutions, such as bleach.

Abstract: Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

Abstract: The present disclosure relates to compositions and methods for treating oral pain. The compositions disclosed herein may comprise a dissolvable carrier containing at least one active ingredient. In some embodiments, the active ingredients comprise guaiacol, eugenol, glycerin, menthol oil, peppermint oil, oregano oil, and/or cardamom oil. The methods disclosed herein comprise treating oral pain in a subject using the compositions disclosed herein, wherein such compositions are configured as a paste that can be molded on or about a surface exhibiting oral pain in a subject's oral cavity. Such compositions are resistant to the moist environment of the subject's oral cavity and provide rapid, effective pain relief in the subject.

Abstract: A therapeutic composition including phenolic compounds derived from Opuntia littoralis (OL) includes an extract of Opuntia littoralis and lutein. The Opuntia littoralis extract can be formed by extracting an Opuntia littoralis plant powder with an alcohol to provide an Opuntia littoralis alcohol extract (OLAE) including the phenolic compounds. In an embodiment, the therapeutic composition can be effectively used as an analgesic for the treatment of pain, as an anti-inflammatory, as a treatment for immunological disorders, and/or as a treatment for oxidant conditions.

Abstract: A method of preventing tissue adhesion includes forming an incision in tissue, applying a hydrogel to tissue through the incision, and closing the incision with the hydrogel therein. The hydrogel includes a polymer non-covalently cross-linked with a plurality of nanoparticles and prevents a formation of adhesions between tissues and/or organs.

Abstract: The present invention relates to a metal (hydr)oxide composite comprising a poorly soluble drug, a method for manufacturing same, and a pharmaceutical composition comprising same.

Abstract: A plastic material for extended release of a bio-active agent, the plastic material comprising a structural polymer, at least one bio-active ingredient embedded within the structural polymer as solid islands, a liquid binding material embedded within the structural polymer as granules, and a carrier liquid absorbed within the liquid-absorbent material. The carrier liquid may be sufficiently non-compatible with the structural polymer so that at least a portion of the carrier liquid is released from the liquid-absorbent material through the structural polymer to an outer surface of the plastic material over a period of time, such as a week or more, a month or more, or about three months. The bio-active agent comprised in the at least one bio-active ingredient may be sufficiently soluble in the carrier liquid at room or body temperature so that the carrier liquid released to the outer surface comprises the bio-active agent in solution.

Abstract: A tissue adhesion prevention hydrogel is provided and engineered with essential features for maintaining separation between tissues and organs in any part of the body, thus preventing adhesion formation, are their shear-thinning, viscoelasticity, and rapid self-healing. A method of using the tissue adhesion prevention hydrogel for tissue adhesion prevention is also provided. A method of interposing the tissue adhesion prevention in between tissue layers for tissue adhesion prevention is further provided.

Abstract: A method of delivering a health care active having the steps of administering to a mammal in need of a health benefit or a treatment for a health condition a personal health care article and consuming the article. The article contains one or more filaments that contain a backbone material, a health care active and optionally aesthetic agents, extensional aids, plasticizers, and crosslinking agents.

Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of channels to increase the ratio of surface area to volume.

Abstract: The present invention provides a formulation of Coenzyme Q10 that can be re-dispersed from a stable dry powder to formulation to yield a nanodispersion that can be readily aerosolized for inhalation.

Abstract: A device for delivery of a first therapeutic agent and a second therapeutic agent to a site in epithelial tissue includes a first layer having a first, freeze-dried polymeric matrix having first and second opposed surfaces, formed by a composition including chitosan, a hydration promoter, a particle adhesion inhibitor, and a particle aggregation inhibitor, and a plurality of first particles embedded within the first matrix so as to be directly surrounded by, and in contact with, the first matrix, the first particles containing the first therapeutic agent and having a coating around the first therapeutic agent, the coating including chitosan. The device further includes a second layer, adjacent to the first layer, having a second, freeze-dried polymeric matrix containing the second therapeutic agent, the first layer and/or the second layer is configured to be attached to the site in the epithelial tissue.

Abstract: A biocompatible and bioresorbable implantable device that is intended to be deployed in the middle meningeal artery through intra-arterial catheters and release an anesthetic agent for a prolonged period into the branches of the middle meningeal artery to treat severe headaches including migraine and trigeminal neuralgias. The implantable device may be a mesh with multiple helical loops, fenestrated collapsible hollow shell or spheroid, or folded sheath.